ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Diagnostic Roles of circXPNPEP3 as Biomarker for Diabetic Nephropathy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is a common chronic microvascular complication of diabetes mellitus (DM). Circular RNAs (circRNAs) have emerged as ideal biomarkers for various diseases. Recent studies have shown that circXPNPEP3 is upregulated in high glucose-induced human umbilical vein endothelial cells. In this study, we aimed to examine the expression levels of circXPNPEP3 in the serum of patients with DN and to evaluate its diagnostic potential for this condition. Methods: The expression levels of circXPNPEP3 in DN tissues and serum were detected using quantitative real-time polymerase chain reaction (qRT-PCR). DN was confirmed by biopsy or clinically defined as a urine albumin/creatinine ratio (uACR) > 30 mg/g or an estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m Results: The expression levels of circXPNPEP3 were significantly upregulated in both DN tissues and serum compared to those in non-DN tissues and serum from healthy controls. The dysregulation of circXPNPEP3 was significantly correlated with albuminuria categories and glomerular filtration rate (GFR) categories. Serum expression of circXPNPEP3 distinguished patients with DN from controls, yielding an area under the ROC curve (AUC) of 0.8389, with a sensitivity of 70.59% and a specificity of 86.27%. Finally, hsa-miR-135b-5p, hsa-miR-135a-3p, and hsa-miR-1237-3p were predicted to be potential targets of circXPNPEP3 in DN, and a competing endogenous RNA (ceRNA) network involving circXPNPEP3 was constructed based on bioinformatic predictions. Conclusion: CircXPNPEP3 is upregulated in DN tissues and serum. Its elevated expression in serum shows promise as a non-invasive diagnostic biomarker for DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.